Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate
Disease area: Respiratory infections



Rating:

Share or cite this content

Citations should be made in the following way:
Mark Andrew Woodhead (Manchester, United Kingdom). Should macrolides be given to all patients with community-acquired pneumonia? Con argument. International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate

Member's Comments

No comment yet.

Related content which might interest you: Should steroids be used in community-acquired pneumonia? Con argument Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate Year: 2017 Should macrolides be given to all patients with community-acquired pneumonia? Pro argument Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate Year: 2017 Are corticosteroids useful in community-acquired pneumonia? Source: Annual Congress 2006 - Evaluation of risk factors in community-acquired pneumonia Year: 2006 Should steroids be used in community-acquired pneumonia? Pro argument Source: International Congress 2017 – Controversies in community-acquired pneumonia: a pro and con debate Year: 2017 The need for macrolides in hospitalised community-acquired pneumonia: propensity analysis Source: Eur Respir J 2007; 30: 525-531 Year: 2007 The approach to antibiotic treatment in community-acquired pneumonia Source: Annual Congress 2008 - MP14 - The approach to antibiotic treatment in community-acquired pneumonia Year: 2008 Corticosteroids for community-acquired pneumonia: are we still there? Source: International Congress 2019 – Severe pneumonia: epidemiology, mechanisms and treatment Year: 2019 Anti-Pseudomonas antibiotic use for hospitalized patients with community-acquired pneumonia Source: Virtual Congress 2020 – Lower respiratory tract infections in clinical practice Year: 2020 Fluoroquinolone versus β-lactam plus macrolide in patients hospitalized with community-acquired pneumonia (CAP) Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 Duration of antibiotic therapy in hospitalised patients with community-acquired pneumonia Source: Eur Respir J 2010; 36: 128-134 Year: 2010 Corticosteroids and community-acquired pneumonia Source: Annual Congress 2007 - Corticosteroids and respiratory failure Year: 2007 Tigecycline vs levofloxacin for the treatment of community-acquired pneumonia (CAP): EU experience Source: Annual Congress 2008 - Treatment and outcome in hospitalised patients with community-acquired pneumonia Year: 2008 Macrolides (alone or in combination) should be used as first-line empirical therapy of community-acquired pneumonia in children: myth or maxim? Source: Breathe, 17 (3) 210056; 10.1183/20734735.0056-2021 Year: 2021 Impact of macrolide therapy on mortality for patients with severe sepsis due to pneumonia Source: Eur Respir J 2009; 33: 153-159 Year: 2009 Ertapenem therapy for community-acquired pneumonia in the elderly Source: Eur Respir J 2005; 26: Suppl. 49, 638s Year: 2005 The comparison of hospitalized healthcare-associated pneumonia with community-acquired pneumonia patients Source: Annual Congress 2010 - Healthcare-associated pneumonia: ventilator-associated pneumonia and pneumonia in hospitalised patients Year: 2010 The impact of empiric antibacterial therapy on mortality for patients hospitalized with community-acquired pneumonia (CAP) Source: Eur Respir J 2006; 28: Suppl. 50, 733s Year: 2006 Mortality in COPD patients with community-acquired pneumonia: who is the third partner? Source: Eur Respir J 2006; 28: 262-263 Year: 2006 COPD: what is the frequency and impact of community-acquired pneumonia? Source: Annual Congress 2008 - Community-acquired pneumonia and COPD: what do we know? Year: 2008